Lupin receives USFDA approval for Generic Ambien CR Extended-release tablets

16 Sep 2013 Evaluate

Lupin has received final approval for its Zolpidem Tartrate Extended?release tablets USP, 6.25 mg and 12.5 mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Sanofi Aventis, US, LLC’s (Sanofi) Ambien CR Extended?release tablets, 6.25 mg and 12.5 mg. The company’s wholly owned US subsidiary Lupin Pharmaceuticals Inc. (LPI) shall commence marketing the product shortly.

Lupin’s Zolpidem CR tablets 6.25 mg & 12.5 mg is the AB rated generic equivalent of Sanofi’s Ambien CR Extended?release tablets, 6.25 mg and 12.5 mg and is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Sanofi’s Ambien CR Extended?release tablets had annual US sales of approximately $366 million, as per IMS MAT March 2013.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×